Wall Street brokerages predict that PetMed Express, Inc. (NASDAQ:PETS) will announce earnings per share of $0.30 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for PetMed Express’ earnings, with the highest EPS estimate coming in at $0.31 and the lowest estimate coming in at $0.28. PetMed Express reported earnings per share of $0.24 during the same quarter last year, which suggests a positive year over year growth rate of 25%. The firm is scheduled to issue its next earnings report on Monday, October 23rd.
On average, analysts expect that PetMed Express will report full year earnings of $1.42 per share for the current year, with EPS estimates ranging from $1.41 to $1.43. For the next financial year, analysts forecast that the business will report earnings of $1.52 per share, with EPS estimates ranging from $1.51 to $1.53. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for PetMed Express.
PetMed Express (NASDAQ:PETS) last released its quarterly earnings data on Monday, July 24th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.07. The firm had revenue of $79.66 million for the quarter, compared to the consensus estimate of $77.32 million. PetMed Express had a net margin of 10.34% and a return on equity of 28.67%. The firm’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 earnings per share.
PETS has been the topic of several research analyst reports. Zacks Investment Research raised shares of PetMed Express from a “sell” rating to a “hold” rating in a research note on Wednesday, April 12th. Craig Hallum cut shares of PetMed Express from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Northcoast Research upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 target price for the company in a report on Monday, July 24th. Finally, Noble Financial reiterated a “hold” rating on shares of PetMed Express in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. PetMed Express has an average rating of “Hold” and an average target price of $35.00.
PetMed Express (NASDAQ:PETS) traded down 0.50% during mid-day trading on Monday, reaching $47.60. 347,522 shares of the company were exchanged. The company’s 50 day moving average price is $41.47 and its 200-day moving average price is $28.88. PetMed Express has a 12 month low of $18.90 and a 12 month high of $50.90. The stock has a market capitalization of $965.90 million, a P/E ratio of 36.62 and a beta of 0.99.
The company also recently declared a quarterly dividend, which will be paid on Friday, August 18th. Stockholders of record on Monday, August 7th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.68%. The ex-dividend date is Thursday, August 3rd. PetMed Express’s dividend payout ratio is 61.54%.
In related news, Director Robert C. Schweitzer sold 2,500 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.18, for a total transaction of $122,950.00. Following the transaction, the director now owns 88,834 shares of the company’s stock, valued at $4,368,856.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert C. Schweitzer sold 5,000 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $48.60, for a total transaction of $243,000.00. Following the transaction, the director now directly owns 83,834 shares in the company, valued at approximately $4,074,332.40. The disclosure for this sale can be found here. In the last three months, insiders sold 68,333 shares of company stock worth $2,497,030. Insiders own 4.00% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in shares of PetMed Express during the second quarter worth about $18,691,000. Renaissance Technologies LLC raised its position in shares of PetMed Express by 11.8% in the first quarter. Renaissance Technologies LLC now owns 1,786,315 shares of the company’s stock worth $35,976,000 after buying an additional 188,615 shares during the period. Dimensional Fund Advisors LP raised its position in shares of PetMed Express by 24.0% in the first quarter. Dimensional Fund Advisors LP now owns 794,669 shares of the company’s stock worth $16,005,000 after buying an additional 153,709 shares during the period. ClariVest Asset Management LLC bought a new position in shares of PetMed Express during the second quarter worth about $3,411,000. Finally, Citadel Advisors LLC raised its position in shares of PetMed Express by 89.8% in the first quarter. Citadel Advisors LLC now owns 153,594 shares of the company’s stock worth $3,093,000 after buying an additional 72,649 shares during the period. 78.98% of the stock is currently owned by institutional investors and hedge funds.
About PetMed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Get a free copy of the Zacks research report on PetMed Express (PETS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
